CASE REPORT

Kidney transplant dysfunction in a patient with COVID – 19 infection: role of concurrent Sars-Cov 2 nephropathy, chronic rejection and vitamin C-mediated hyperoxalosis: case report

Urmila Anandh1, Swarnalata Gowrishankar2*, Alok Sharma3, Alan Salama4 and Indranil Dasgupta5

Abstract

Background: COVID-19 infection in kidney transplant recipients often lead to allograft dysfunction. The allograft injury has various histopathological manifestations. Our case illustrates the unusual combination of allograft rejection, acute kidney injury secondary to oxalate nephropathy and SARS CoV-2 nephropathy as the cause of irreversible allograft failure.

Case presentation: A 56 year old renal allograft recipient presented with a history of fever and diarrhoea for the preceding 4 weeks, tested positive for Sars-CoV2 on nasal swab and was found to have severe allograft dysfunction, necessitating haemodialysis. He subsequently underwent an allograft biopsy, which demonstrated antibody mediated rejection along with the presence of extensive oxalate deposition in the tubules. Ultrastructural examination demonstrated spherical spiked particles in the glomerular capillary endothelium and the presence of tubulo-reticular inclusions suggestive of an active COVID-19 infection within the kidney. The intra-tubular oxalate deposition was considered to be the result of high dose, supplemental Vitamin C used as an immune booster in many patients with COVID – 19 infection in India.

Conclusions: This case highlights the complex pathology that may be seen in following COVID-19 disease and the need for kidney biopsies in these patients to better understand the aetiology of disease.

Keywords: COVID-19 nephropathy, Kidney transplant, Oxalate nephropathy, Tubulo-reticular inclusions

Background

COVID-19 infection in kidney transplant recipients often results in serious consequences. Many require hospitalisation and have high rates of mortality [1]. Transplant recipients are at an increased risk of adverse outcomes because of their associated comorbidities and immunosuppressive therapy. A common manifestation in these patients is worsening allograft function [2]. The treatment of these patients is often challenging and need individualised care [3]. The complex therapeutic regimens along with inadequate knowledge about the mechanisms of allograft injury secondary to COVID-19 infection add to the problem in many instances as illustrated in our case.
Case presentation
The patient was a 56 year old renal allograft recipient whose kidney was donated by his wife, 8 years previously, and was maintained on triple immunosuppression (tacrolimus, mycophenolate sodium and prednisolone). He had a past history of ischaemic heart disease, and had undergone a percutaneous transluminal coronary angioplasty two years earlier. He presented to his local hospital with a history of fever and diarrhoea, and was noted to have acute allograft dysfunction (serum creatinine on admission 3.8 mg/dl, previous reading three months earlier had been 1.2 mg/dl). Stool routine and culture as well as ultrasound of the abdomen were performed and were non-contributory. The possibility of COVID–19 infection was considered. He was managed conservatively with intravenous fluids and antibiotics (amoxycillin sulbactam 1.2 g twice a day and metronidazole 500 mg three times a day for 7 days) to treat his diarrhoea. His mycophenolate sodium was stopped and tacrolimus dose was halved. Prednisolone was increased to 20 mg/day. Since, at the time of the first pandemic wave, early data suggested a potential benefit of hydroxychloroquine, he was started on this as well as zinc and vitamin C. However, he showed no clinical improvement, and was transferred to our hospital.

In addition to his previous history, he admitted to reduced urine output, swelling of his legs and progressive breathlessness. On clinical examination, there were presence of fever, tachypnea and a low oxygen saturations of 92% on room air. Further evaluation revealed moderate left ventricular (LV) dysfunction on echocardiography associated with raised serum pro-BNP level. He was investigated for COVID–19 infection and his SARS CoV-2 RT-PCR was positive. His serum C-reactive protein and D-dimer levels were high, and he had progressive allograft dysfunction. The 12 h trough tacrolimus levels were 5.2 ng/ml. His CT chest showed mosaic attenuation of both lungs and ground glass opacities. (Table 1) His CMV PCR showed undetectable viral counts. He was initiated on haemodialysis and treated according to our protocol for COVID-19 infection (intravenous dexamethasone, anticoagulation, remdesivir, vitamin C and

Table 1 Laboratory and radiological investigations in our hospital

| Parameter                      | Value | Normal Range          |
|-------------------------------|-------|-----------------------|
| Haemoglobin                   | 10.3  | 13–17 g%              |
| Total Leucocyte count         | 4220  | 4000–10,000 cells/cumm|
| Creatinine                    | 5.5   | 0.5–1.04 mg/dl        |
| Electrolytes                   |       |                       |
| Sodium                        | 138   | 137–145 mmol/L        |
| Potassium                     | 5.4   | 3.5–5.1 mmol/L        |
| Bicarbonate                   | 16    | 17–28 mmol/L          |
| Sars Cov-2 RT PCR             | Positive |                   |
| LDH                           | 250   | 120–246 U/L           |
| C-Reactive Protein            | 15    | <0.5 mg/dl            |
| D-dimer                       | 1002.1| <500 ng/ml (FEU)      |
| Ferritin                      | 139   | 11.1–264 ng/ml        |
| Troponin-I                    | 0.22  | 0.0–0.12 ng/dl        |
| NT Pro BNP                    | 17,875| <125 pg/ml            |
| Ultrasound Abdomen            | Mild Hepatomegaly |                   |
|                               | Ascites |                       |
|                               | Allograft doppler Resistivity Indices –0.8-91 |           |
| Chest X Ray                   | Cardiomegaly |                |
|                               | Bilateral Pleural Effusions |            |
| Computed Tomography Chest     | Cardiomegaly |                |
|                               | Bilateral Pleural Effusions |            |
|                               | Mosaic attenuation of both lungs |         |
|                               | Ground glass opacities |            |
| Echocardiography              | Dilated Chambers |                |
|                               | Ejection Fraction-35% |            |
|                               | Moderate TR/VMR |            |
|                               | Apex Akinetic |            |
|                               | Anterior wall Hypokinetic |         |
|                               | Minimal Pericardial Effusion |       |
antibiotics). Hydroxychloroquine was stopped. He underwent an allograft biopsy as his renal function did not improve over the following two weeks. The renal biopsy showed the evidence of glomerulitis and segmental basement membrane duplication. The tubules showed marked injury with denudation of the lining and about 20% of the tubules had intraluminal refractile oxalate crystals. There was peritubular capsular dilatation with mild to moderate capillaritis. Focal arteriolar hyalinosis and mild intimal fibrosis were also evident (Fig. 1).

C4d immunohistochemistry showed strong peripheral linear staining along some segments of the glomerulus. Occasional peritubular capillaries (1%) also showed circumferential linear positivity (Fig. 1). The final diagnosis based on histopathology was chronic active antibody mediated rejection. There was associated acute tubular injury with extensive oxalate crystal deposition. Electron microscopy (EM) revealed prominent subendothelial rarefaction, reduplication of basement membrane and peritubular capillary basement membrane multi-layering (Fig. 2). The ultrastructural findings of spherical spiked particles (Fig. 3) and tubulo-reticular inclusions in the glomerular capillary endothelial cytoplasm (Fig. 4) were suggestive of an active COVID – 19 infection of the kidney.

The management of chronic active rejection requiring augmented immunosuppression was discussed with the patient and family; however, this was declined and the patient continued on intermittent haemodialysis. Respecting the family’s wish, no further investigations for the evaluation of antibody mediated rejection (such as donor specific antibody levels) and oxalate nephropathy (blood/urine oxalate levels) were done. A week after his allograft biopsy, he developed rapid deterioration of his cardiac function (repeat echocardiography showed an ejection fraction of 20%) and died. The clinical history from the time of his transplantation and his unfortunate demise is summarised as a timeline graphic. (Fig. 5).

Discussion and conclusions
This case demonstrates a myriad of renal abnormalities related to alloimmune injury, COVID-19 infection and its treatment. Chronic active antibody mediated rejection was confirmed by the findings of glomerulitis, early transplant glomerulopathy and mild peritubular capillaritis which was further substantiated on EM. C4d staining showed a strong linear positivity along the glomerular basement membrane (GBM) and along a few peritubular capillary walls, which was again seen as electron dense lines along the GBM on EM. Hyperinflammatory response in multiple organ systems, including renal, is believed to be common in COVID-19 infection [4], but the link between this exaggerated immune response and the risk of rejection in allograft recipients infected by the SARs CoV-2 virus is unclear [5]. Serial measurements of
Donor specific antibodies might have helped us in planning his immunosuppressive therapy.

The second interesting finding was that of acute tubular injury with birefringent oxalate crystals in the tubule lumina. Besides oxalate, birefringent intratubular crystal formation is seen with drugs such as ceftriaxone [6] and the proteosome inhibitor darunavir [7], but, to our knowledge, has not been reported with remdesivir. The crystals were typically fan-shaped, colourless and birefringent, and thus most likely to be oxalate crystals. This was considered to be a form of secondary hyperoxaluria as the patient did not have any previous history of stone disease. We postulate that it was related to the excessive use of vitamin C in our patient; the patient had received vitamin C at a dose of 500 mg three times a day for over a month. Though the lack of oxalate levels in blood and urine are a limitation that needs to be considered. High doses of vitamin C supplementation is commonly used in COVID-19 infection in India to counter the potential cytokine storm. There have been three other recent reports of dialysis dependent acute kidney injury with oxalate nephropathy in patients with COVID-19; two due to excessive vitamin C intake, both recovering after more than 45 days of hospitalisation [8], and one in a patient with collapsing focal segmental glomerulosclerosis [9].

The third interesting biopsy finding was the demonstration of virus-like particles with spikes and tubulo-reticular inclusions indicative of viral infection within the endothelial cell cytoplasm. Su et al. in their autopsy series, described 9 cases with significant proximal tubular injury in whom ultrastructural studies demonstrated virus like particles in podocytes, proximal tubular epithelium and endothelium [10]. Viral-like particles were also noted in some cases in a recent biopsy series from the Mayo Clinic, but no definitive SARS-CoV-2 virions were seen in glomerular or tubular cells on electron microscopy [11]. A recent post-mortem series has been able to culture the virus thus suggesting that the virus is viable in the kidney. The authors suggest that direct viral infection may increase the risk of acute kidney injury [12]. The significance of the presence of viral particles in the glomerular endothelium and its impact on the irreversible acute kidney injury in our patient needs to be elucidated further.
Reports of COVID-19 infection in renal transplant recipients have been varied with the first report of 15 renal transplant recipients from the Columbia Transplant Registry Program reporting outcomes similar to that in the general population [2]. In contrast, a study from UK reported that 5 out of 7 transplant recipients with COVID-19 had severe infection requiring intensive care and 1 out of 7 died [13]. The differences in outcome from centres may reflect the differences in severity of COVID-19 infection, the treatment strategies adopted and the duration of follow up [14, 15].

Complex interactions occur when there is COVID-19 infection in kidney transplant recipients as exemplified by this patient. Chronic active antibody mediated rejection would have been managed routinely, but the renal tubular injury was accelerated by oxalate crystals related to iatrogenic hypervitaminosis C and active COVID-19 infection of the allograft. Viral and iatrogenic injuries need to be kept in mind when reporting on these allograft biopsies and managing such cases. Physicians also should limit the use of drugs which may potentiate kidney damage in renal allograft recipients.

Abbreviations
COVID-19: Coronavirus disease-19; SARS CoV-2: Severe acute respiratory syndrome coronavirus 2; LDH: Lactate Dehydrogenase; RT-PCR: Real Time Polymerase Chain Reaction; NT-pro BNP: N terminal B-type Natriuretic Peptide; TR: Tricuspid Regurgitation; MR: Mitral Regurgitation

Acknowledgements
Not applicable.

Authors’ contributions
Dr. UA was the clinician responsible for taking care of the patient and writing the first draft. Dr. SG was responsible reporting the histopathology of the allograft biopsy and contributed to the histopathology discussion. Dr. AS was responsible for the electron microscopic interpretation and the images of the allograft biopsy. Profs AS and ID contributed in the discussion of the clinical management of the case. They were responsible for review and revision of the paper, and for the final approval of the paper. All authors have read and approved the manuscript.

Funding
None.

Availability of data and materials
The datasets used during the writing of the case report is available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Ethics approval taken from IRB Yashoda Hospitals Secundearbad (RP 8P/20).

Consent for publication
Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Nephrology, Yashoda Hospitals, Secunderabad 500003, India. 2Department of Pathology, Apollo Hospitals, Jubilee Hills, Hyderabad 500044, India. 3Dr LalPathlabs National Reference Laboratory, Rohini, New Delhi 110085, India. 4Department of Renal Medicine, Royal Free Hospital, University College London, NW3 2PF, London, UK. 5Department of Renal Medicine, Heartlands Hospitals, Birmingham, Warwick Medical School University of Warwick, Warwick, UK.
References

1. Akalin E, Azzi Y, Bartash R, Seetharamulu H, Patdes M, Hemmige V, Ross M, Forrest S, Goldstein YD, Ajajmy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. Covid-19 and kidney transplantation. N Engl J Med. 2020;328(25):25–2477. https://doi.org/10.1056/NEJMc2111177.

2. Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. J Am Soc Nephrol. 2020;31(6):1150–6. https://doi.org/10.1681/ASN.2020030376.

3. Caillard S, Anglicheau D, Matignon M, Durrbach A, Greze C, Frimat L, et al. on behalf of the French SOT COVID registry. An initial report from the French SOT COVID registry suggests high mortality due to Covid–19 in recipients of kidney transplants. Kidney Int. 2020. https://doi.org/10.1016/j.kint.2020.03.005.

4. Tay MZ, Poh CM, Renia L, MacAry P, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. https://doi.org/10.1038/s41577-020-0311-8.

5. Aziz F, Muth B, Parajuli S, Garg N, Mohamed M, Mandelbrot D, Djamali A. Unusually high rates of acute rejection during the COVID-19 pandemic: cause for concern? Kidney Int. 2020;98(2):13–4. https://doi.org/10.1016/j.kint.2020.05.038.

6. Daudon M, Frochot V, Bazin D, Jungers P. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163–201. https://doi.org/10.1007/s40265-017-0853-7.

7. Soto K, Campos P, Hanlon R, Antunes AMM, Morello J, Perazella MA. Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy. Kidney Int. 2018;93(3):494–9. https://doi.org/10.1016/j.kint.2018.11.014.

8. Fontana F, Cazzato S, Giovanella S, Ballestri M, Leonelli M, Mori G, Alfano G, Magistroni R, Cenacchi G, Antoniotti R, Cappelli G. Oxalate nephropathy caused by excessive vitamin C administration in 2 patients with COVID-19. Kidney Int. Rep. 2020 Oct;5(10):1815–22. https://doi.org/10.1016/j.ekir.2020.07.008.

9. Mallhotra V, Nagoon S, Troyer DA, McCune TR. Collapsing focal segmental glomerulosclerosis and acute oxalate nephropathy in a patient with COVID-19: a double whammy. J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620963635. https://doi.org/10.1177/2324709620963635.

10. Su H, Yang M, Wan C, Li X, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C. Renal histopathological analysis of 26 post mortem findings of patients with COVID-19 in China. Kidney Int. 2020 Jul;98(1):219–27. https://doi.org/10.1016/j.kint.2020.04.003.

11. Nasr SH, Alexander MP, Cornell LD, Herrera LH, Fidler ME, Said SM, Zhang P, Larsen CP, Sethi S. Kidney biopsy findings in patients with COVID-19, kidney injury and proteinuria. Am J Kidney Dis. 2020. https://doi.org/10.1053/j.ajkd.2020.11.002.

12. Aepfelbacher M, Puelles VG, Huber TB. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet. 2020;396(10251):598–9. https://doi.org/10.1016/S0140-6736(20)31754-2.

13. Banerjee D, Popoola J, Shah S, Ster K, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020 Jun;97(6):1076–82. https://doi.org/10.1016/j.kint.2020.02.018.

14. Kant S, Menez SP, Hanouneh M, Fine DM, Creeks DC, Brennan DC, Sperati CJ, Jaar BG. The COVID-19 nephrology compendium: AKI, CKD, ESKD, and transplantation. BMC Nephrol. 2020;21(1):449–62. https://doi.org/10.1186/s12882-020-02112-0.

15. Nair V, Jandovitz N, Jhaeveri KD, Molmenti E. COVID-19 and solid organ transplant outcomes. Nephrol Dial Transplant. 2020;35(8):1444–6. https://doi.org/10.1093/ndt/gfaa207.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.